BTAI

BioXcel Therapeutics' stock has experienced volatility over the past six months. The stock price ranged between $1.01 and $8.08 over the past 52 weeks, and as of early May 2026, it was trading around $1.21-$1.22, representing a decrease of approximately 23.8% since the beginning of 2026. In April 2026, BioXcel Therapeutics announced a virtual event to discuss the commercial launch plan for IGALMI in the at-home setting and issued warrants in a private equity financing deal. H.C. Wainwright maintained a "Buy" rating but cut its price target from $6 to $5 in April 2026, citing concerns over recent and expected equity dilution. In early April 2026, BioXcel Therapeutics announced the enrollment of the first patients in a U.S. Department of War-funded study of BXCL501 for the treatment of acute stress reactions. The FDA accepted a Supplemental New Drug Application (sNDA) for the use of IGALMI in the at-home setting in April 2026. In March 2026, the company reported its Fourth Quarter and Full-Year 2025 financial results as it prepared for potential IGALMI approval in the outpatient setting. The company's auditor has raised a "going concern" doubt, and a pattern of direct offerings and warrant issuances indicates persistent balance sheet stress. Shareholders have been substantially diluted in the past year, with a 66% increase in shares outstanding.